Black Diamond Therapeutics reported net income of -$9.94M for the quarter ended Jun 2026. This income statement covers 31 quarters of results from Dec 2018 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||||||||||||||||||||||
| Revenue | 70.00M | ||||||||||||||||||||||||||||||
| Operating items | |||||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 27.63M | 19.66M | 17.79M | 16.20M | 15.85M | 14.61M | 14.75M | 13.15M | 16.15M | 15.29M | 13.54M | 12.56M | 12.91M | 12.30M | 10.51M | 9.32M | 7.44M | 6.30M | 7.00M | 7.39M | |||||||||||
| Selling, General & AdministrativeSG&A | 7.74M | 6.42M | 7.89M | 6.98M | 6.28M | 7.24M | 6.81M | 6.88M | 7.86M | 5.57M | 6.70M | 9.57M | 5.22M | 5.98M | 4.96M | 4.10M | 3.54M | 3.97M | 4.26M | 4.66M | |||||||||||
| Other Operating ExpensesOther Opex | 7.35M | ||||||||||||||||||||||||||||||
| Operating ExpensesOpex | 35.36M | 26.08M | 25.68M | 23.17M | 22.12M | 21.85M | 21.56M | 20.03M | 24.01M | 20.86M | 20.25M | 22.13M | 18.13M | 18.27M | 15.47M | 13.42M | 10.98M | 17.61M | 11.26M | 12.06M | |||||||||||
| Operating IncomeOp. Inc | -35.36M | -26.08M | -25.68M | -23.17M | -22.12M | -21.85M | -21.56M | -20.03M | -24.01M | -20.86M | -20.25M | -22.13M | -18.13M | -18.27M | 54.53M | -13.42M | -10.98M | -17.61M | -11.26M | -12.06M | |||||||||||
| EBIT | -35.36M | -26.08M | -25.68M | -23.17M | -22.12M | -21.85M | -21.56M | -20.03M | -24.01M | -20.86M | -20.25M | -22.13M | -18.13M | -18.27M | 54.53M | -13.42M | -10.98M | -17.61M | -11.26M | -12.06M | |||||||||||
| Non-operating items | |||||||||||||||||||||||||||||||
| Non Operating Interest Expenses | |||||||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.78M | 0.59M | 0.41M | 0.39M | 0.56M | 0.68M | 0.62M | 0.54M | 0.44M | 0.32M | 0.64M | 0.46M | 0.52M | 0.56M | 0.59M | 1.12M | 1.16M | 1.18M | 1.02M | 0.92M | |||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.49M | -0.38M | -0.23M | -0.14M | -0.09M | 0.12M | 0.06M | 0.34M | 0.57M | 1.12M | 1.38M | 1.76M | 2.06M | 1.73M | 1.42M | 1.74M | 1.32M | 1.31M | 1.20M | 1.23M | |||||||||||
| Non Operating IncomeNon Op. Inc. | 0.29M | 0.21M | 0.17M | 0.24M | 0.47M | 3.02M | 0.69M | 0.88M | 1.00M | 1.45M | 2.02M | 2.22M | 2.57M | 2.29M | 2.01M | 2.86M | 2.48M | 2.49M | 2.22M | 2.15M | |||||||||||
| Net income details | |||||||||||||||||||||||||||||||
| EBT | -34.59M | -25.49M | -25.27M | -22.79M | -21.56M | -21.18M | -20.94M | -19.49M | -23.57M | -20.53M | -19.61M | -21.67M | -17.61M | -17.71M | 55.12M | -12.30M | -9.81M | -16.43M | -10.24M | -11.13M | |||||||||||
| Profit After TaxPAT | -35.15M | -26.42M | -25.51M | -22.93M | -21.86M | -20.41M | -20.88M | -19.15M | -23.01M | -19.41M | -18.23M | -19.91M | -15.56M | -15.98M | 56.54M | -10.57M | -8.50M | -15.16M | -9.04M | -9.94M | |||||||||||
| Income from Continuing OperationsIncome (Continuing) | -34.59M | -25.49M | -25.27M | -22.79M | -21.56M | -21.18M | -20.94M | -19.49M | -23.57M | -20.53M | -19.61M | -21.67M | -17.61M | -17.71M | 55.12M | -12.30M | -9.81M | -16.43M | -10.24M | -11.13M | |||||||||||
| Consolidated Net IncomeConsol Net Inc. | -34.59M | -25.49M | -25.27M | -22.79M | -21.56M | -21.18M | -20.94M | -19.49M | -23.57M | -20.53M | -19.61M | -21.67M | -17.61M | -17.71M | 55.12M | -12.30M | -9.81M | -16.43M | -10.24M | -11.13M | |||||||||||
| Income towards Parent CompanyParent Net Inc | -34.59M | -25.49M | -25.27M | -22.79M | -21.56M | -21.18M | -20.94M | -19.49M | -23.57M | -20.53M | -19.61M | -21.67M | -17.61M | -17.71M | 55.12M | -12.30M | -9.81M | -16.43M | -10.24M | -11.13M | |||||||||||
| Net Income towards Common StockholdersNet Income | -34.59M | -25.49M | -25.27M | -22.79M | -21.56M | -21.18M | -20.94M | -19.49M | -23.57M | -20.53M | -19.61M | -21.67M | -17.61M | -17.71M | 55.12M | -12.30M | -9.81M | -16.43M | -10.24M | -11.13M | |||||||||||
| Additional items | |||||||||||||||||||||||||||||||
| EPS (Basic) | -0.95 | -0.70 | -0.70 | -0.63 | -0.59 | -0.58 | -0.57 | -0.53 | -0.46 | -0.47 | -0.38 | -0.39 | -0.31 | -0.32 | 0.97 | -0.22 | -0.17 | -0.29 | -0.18 | -0.19 | |||||||||||
| EPS (Diluted) | -0.95 | -0.70 | -0.70 | -0.63 | -0.59 | -0.58 | -0.57 | -0.53 | -0.46 | -0.47 | -0.38 | -0.39 | -0.31 | -0.32 | 0.96 | -0.22 | -0.17 | -0.29 | -0.18 | -0.19 | |||||||||||
| Shares Outstanding | 36.22M | 36.19M | 36.27M | 36.29M | 36.35M | 36.33M | 36.48M | 36.52M | 50.94M | 43.95M | 51.81M | 55.16M | 56.51M | 55.03M | 56.66M | 56.80M | 56.93M | 56.87M | 57.23M | 57.37M | |||||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 36.22M | 36.19M | 36.27M | 36.29M | 36.35M | 36.33M | 36.48M | 36.52M | 50.94M | 43.95M | 51.81M | 55.16M | 56.51M | 55.03M | 57.67M | 56.80M | 56.93M | 57.56M | 57.23M | 57.37M | |||||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 36.23M | 36.23M | 36.29M | 36.32M | 36.37M | 36.43M | 36.51M | 36.53M | 51.64M | 51.65M | 52.53M | 56.41M | 56.52M | 56.64M | 56.68M | 56.89M | 56.94M | 57.14M | 57.30M | 57.45M | |||||||||||
| EBITDA | -35.36M | -26.08M | -25.68M | -23.17M | -22.12M | -21.85M | -21.56M | -20.03M | -24.01M | -20.86M | -20.25M | -22.13M | -18.13M | -18.27M | 54.53M | -13.42M | -10.98M | -17.61M | -11.26M | -12.06M | |||||||||||
| Interest ExpensesInt Expense |